New Treatment for Venous Malformations

 
A Venous Malformation is a type of vascular anomaly that affects one in every 2,000 people (aproximately 6,000 estimated in Belgium alone). 
 
This chronic disease, impossible to cure at the moment, is a vascular anomaly affecting the veins and can be present in any part of the human body. In 2009, the teams led by Prof. Miikka Vikkula and Prof. Laurent Boon discovered the root cause of this pathology: a mutation of a gene baptised TIE21. Thanks to this advance, belgian researchers collaborating with the team led by Prof. Joyce Bischoff (from Harvard Medical School in Boston, USA) could create for the first time a model of the pathology, and implant human cells containing the mutation onto laboratory mice. These mice have therefore developped lesions that are identical to those that we find on humans affected by venous malformations. 
 
This research path allowed them to discover that various molecules were abnormally hyperactives in the formation of the venous malformations, particularly the protein mTOR. The rapamycine, an inhibitor of the mTOR molecule, is a drug used for many years to treat other diseases. Following the research, a clinical trial led by the Center for Vascular Anomalies of Saint-Luc Hospital, in Brussels, proved the efficaccy of this drug for treating venous malformations. 
 
If you are interested in having more information about this clinical trial, it is best to check the information communicated by the Saint Luc Hospital (in French):
 
 
You can also find additional information through articles in general media in Belgium (also in French):
 
 
For any details, it is best to address the Center for Vascular Malformations directly.